These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25604887)

  • 1. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.
    Narayan V; Vaughn D
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):731-42. PubMed ID: 25604887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative chemotherapy for muscle invasive bladder cancer.
    Rudzinski JK; Basappa NS; North S
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):249-54. PubMed ID: 26125306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.
    Sfakianos JP; Galsky MD
    Urol Clin North Am; 2015 May; 42(2):181-7, viii. PubMed ID: 25882560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.
    Balar AV; Milowsky MI
    Urol Clin North Am; 2015 May; 42(2):217-24, viii-ix. PubMed ID: 25882563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
    Sternberg CN; Parmar MK
    J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neoadjuvant chemotherapy for invasive bladder cancer].
    Kageyama Y; Kihara K
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
    Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    Lemiński A; Kaczmarek K; Byrski T; Słojewski M
    PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy for bladder cancer.
    Sonpavde G; Petrylak DP
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):133-44. PubMed ID: 15990329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.